Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Modern Blood Banking and Transfusion in Clinical Practice: Second Edition
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Modern Blood Banking and Transfusion in Clinical Practice: Second Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 25 May 2026 | Viewed by 3219

Special Issue Editor

Dr. Pilar Solves

E-Mail Website
Guest Editor
Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
Interests: blood transfusion; patient blood management; blood banking; immunohematology; cell therapy; transplantation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to the Special Issue “Modern Blood Banking and Transfusion in Clinical Practice: Second Edition”. This is a new edition; we published four papers in the first volume. For more details, please visit https://www.mdpi.com/journal/jcm/special_issues/Blood_Banking_Transfusion.

Blood banking and blood component transfusion practices have improved considerably over the years. Some of the notable changes are the increasing automatization of compatibility testing and the implementation of electronic systems to monitor the transfusion process to record adverse effects; however, in the last decade blood banks have faced new problems. The use of monoclonal antibodies, such as anti-CD38 and anti-CD47, for the treatment of patients with malignancies is a concern, since these treatments produce interference with pretransfusion compatibility tests, delaying blood availability. In addition, the infusion of cell therapy products is carried out by blood bank staff in many countries. Therefore, blood banks must be on alert to provide a response to these new challenges in a timely manner.

Transfusion is one of the most widely used therapies, sometimes involving inappropriate episodes. Benefits and risks have to be carefully considered in each clinical situation when a blood transfusion is requested. Over the last decade hemovigilance systems have detected a decline in red blood cell usage, which could be explained in part by the incorporation of restrictive strategies based on current scientific evidence. In fact, patient blood management programs are being progressively incorporated into clinical practice in order to reduce unnecessary blood exposure and improve patient outcomes.

The aim of this Special Issue is to provide updates on the most relevant advances in blood banking laboratory and transfusion practise, focusing on those situations in which transfusion can be  challenging, such as sickle cell disease, solid organ transplantation, massive transfusion, and cell therapy recipients, among others.

Dr. Pilar Solves
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood transfusion therapy
  • patient blood management
  • restrictive transfusion
  • cell therapy
  • platelet transfusion

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1500 KB  
Article
Ex Vivo Evaluation of CD3+CD8+ T Cell Subpopulations in Red Blood Cell Concentrates: Does Storage Time Play an Important Role?
by Salih Haldun Bal, Levent Tufan Kumas, Lacin Cevhertas, Izel Yilmaz, Pinar Hiz-Ellergezen, Ferah Budak-Sener, Yasemin Heper and Haluk Barbaros Oral
J. Clin. Med. 2026, 15(3), 1178; https://doi.org/10.3390/jcm15031178 - 3 Feb 2026
Viewed by 387
Abstract
Background/Objectives: Our study was designed to explore the potential role of allogeneic CD8+ T lymphocytes present in red blood cell concentrates (RBCs) in the development of transfusion-related immunomodulation (TRIM) and the effect of storage time on these cells. Methods: From [...] Read more.
Background/Objectives: Our study was designed to explore the potential role of allogeneic CD8+ T lymphocytes present in red blood cell concentrates (RBCs) in the development of transfusion-related immunomodulation (TRIM) and the effect of storage time on these cells. Methods: From six units of whole blood, donated by volunteers, RBCs were obtained and each one was divided into three equal parts to provide the samples for storage days 0, 21, and 42. On related days, mononuclear cells (MNCs) were isolated from these RBC samples. MNCs were cultured, and phytohemagglutinin was added to half of the culture wells to stimulate the cells and achieve T cell division. Supernatants and MNCs were obtained from stimulated (STI) and unstimulated (US) wells. Supernatants were used for cytokine analyses, while MNCs were used to investigate the T cells and transcription factors. Results: The frequency of CD8+ T lymphocytes (Tc), their subgroups (Tc1, Tc2, and Tc17), specific transcription factors, and effector cytokines decreased during the storage time, but cell viability increased. CD3+CD8+TNF-α+ cells were significantly higher in the STI group on day 0 compared to the US group. Other cells did not respond to the mitogen (phytohemagglutinin) stimulation. Conclusions: During storage, the number of Tc cells and their ability to respond to mitogens decreased over time. The unresponsiveness was not recovered in ex vivo cell culture. Our findings suggest that transfused Tc cells are unlikely to be primary mediators of TRIM. Full article
(This article belongs to the Special Issue Modern Blood Banking and Transfusion in Clinical Practice: Second Edition)
►▼ Show Figures

Graphical abstract

14 pages, 2907 KB  
Article
Specific Trends in Blood Utilization During the COVID-19 Pandemic: A Retrospective Analysis of a Hungarian Clinical Centre
by Sándor Pál, Margit Solymár, Barbara Réger, Hussain Alizadeh, András Vereczkei, Tamás Kiss and Zsuzsanna Faust
J. Clin. Med. 2025, 14(22), 7943; https://doi.org/10.3390/jcm14227943 - 9 Nov 2025
Viewed by 646
Abstract
Background/Objectives: The COVID-19 pandemic significantly disrupted healthcare systems and blood supply chains. This study aimed to analyze blood transfusion trends across three distinct clinical departments in a Hungarian tertiary care clinical center and to examine the relationship between these trends and the pandemic [...] Read more.
Background/Objectives: The COVID-19 pandemic significantly disrupted healthcare systems and blood supply chains. This study aimed to analyze blood transfusion trends across three distinct clinical departments in a Hungarian tertiary care clinical center and to examine the relationship between these trends and the pandemic waves. Methods: A retrospective analysis of hospitalization and transfusion data from the Departments of Anesthesiology and Intensive Therapy, Surgery, and the Division of Hematology at the University of Pécs Clinical Centre was performed between 1 January 2020, and 31 December 2023. Generalized additive models were employed to assess the association between available predictors and the odds and volume of red blood cell transfusions. Results: At the Department of Anesthesiology and Intensive Therapy, the median weekly ratio of transfused patients fell from 50% (pre-pandemic) to 9.76% (third wave of pandemic). COVID-19 diagnosis was associated with lower odds of receiving transfusion (OR: 0.23) and with a lower incidence rate ratio of transfused red blood cells (IRR: 0.22). At the Department of Surgery, the median weekly ratio of transfused patients was consistently low and stable (9–10%) throughout the study period. The number of patients remained relatively stable at the Division of Hematology during the study period, expressing a higher odds of receiving transfusion during the second (OR: 2.63) and fourth (OR: 1.52) pandemic waves. Conclusions: The pandemic’s impact on transfusion practice, driven by indirect various consequences of patient redirection and protocol modifications, was most expressed at the Department of Anesthesiology and Intensive Therapy. Similar changes in transfusion practice may be anticipated in the event of another pandemic outbreak. Full article
(This article belongs to the Special Issue Modern Blood Banking and Transfusion in Clinical Practice: Second Edition)
►▼ Show Figures

Figure 1

9 pages, 215 KB  
Article
Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single Center
by Lara Eritzpokhoff, Ernesto Talegón De La Fuente, Aida Carril Barcia, Pedro Asensi Cantó, Ines Gómez Segui, Mario Arnao Herraiz, Javier De La Rubia Comos and Pilar Solves Alcaina
J. Clin. Med. 2025, 14(16), 5754; https://doi.org/10.3390/jcm14165754 - 14 Aug 2025
Viewed by 1251
Abstract
Background/Objectived: Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of multiple myeloma. Its use interferes with the indirect antiglobulin test (IAT). Treatment of reagent red blood cells (RBCs) with dithiothreitol (DTT) is one of the most validated techniques to resolve this [...] Read more.
Background/Objectived: Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of multiple myeloma. Its use interferes with the indirect antiglobulin test (IAT). Treatment of reagent red blood cells (RBCs) with dithiothreitol (DTT) is one of the most validated techniques to resolve this interference. The objective of this study is to evaluate the rate of alloimmunization in transfused patients receiving daratumumab and the occurrence of hemolytic transfusion reactions. Materials and Methods: We conducted a single-center, retrospective, descriptive analysis of all patients treated with daratumumab at our institution from October 2016 to April 2024. For daratumumab-treated patients requiring RBC transfusions, an IAT with DTT-pretreated RBCs (DTT-IAT) was performed using the automated Orthovision system. Transfusion was administered only with a previous negative DTT-IAT while respecting Rh and Kell phenotyping. We assessed the transfusion profile of our patient cohort, including their rates of alloimmunization before and after daratumumab initiation, as well as the incidence of hemolytic complications. Additionally, a literature review was performed on reported alloimmunization rates in daratumumab-treated patients. Results: Among all patients, 106 received RBC and/or platelet transfusions after starting daratumumab. Four had known pre-existing alloantibodies. None developed new alloantibodies or experienced hemolytic complications while receiving anti-CD38 therapy. There were four cases of false-positive DTT-IAT due to residual drug interference or technical variability, in which no alloantibodies or adverse transfusion reactions were detected. Conclusions: Patients receiving daratumumab exhibit a low risk of alloimmunization. This may be partly explained by adherence to Rh and Kell phenotyping and daratumumab’s immunosuppressive effects on alloantibody production. These results support the conclusion that an extended red blood cell phenotype or genotype before starting daratumumab could be omitted if a fast and reliable technique for pretransfusion testing (such as automated DTT-IAT) is available 24 h. Full article
(This article belongs to the Special Issue Modern Blood Banking and Transfusion in Clinical Practice: Second Edition)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop